A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 WildType, Advanced or Recurrent Endometrial Carcino

Clinical Trial Grant

Duke Scholars

Principal Investigator Angeles Alvarez Secord Obstetrics and Gynecology, Gynecologic Oncology

Administered By

Duke Cancer Institute

Awarded By

Karyopharm Therapeutics

Start Date

July 31, 2023

End Date

July 31, 2028

Administered By

Duke Cancer Institute

Awarded By

Karyopharm Therapeutics

Start Date

July 31, 2023

End Date

July 31, 2028